Speakers

Elsa Abranches holds a degree in Chemical Engineering and a Ph.D. in Stem Cell Biotechnology, from the Technical University of Lisbon, Portugal. Elsa has over 20 years of experience in stem cell biotechnology, standardization and Advanced Therapies regulation areas, ranging from applied research...

Khalid Al-Kinani is a distinguished Professor and Department Chair at the University of Baghdad, renowned for his expertise in the field of biologics. He also serves as a mamber of the 2nd Medicines Reguistration Committee at the Iraqi Ministry of Health (MOH) and a former Head of Biologics and...

Antonio is a Senior Scientist in AstraZeneca’s Biologics Engineering—Protein Engineering and New Modalities division, specialising in pre-clinical biopharmaceutical development. His expertise lies in bioconjugation chemistry and the design of advanced protein conjugates, helping to shape innovative ...

Dr. Can Araman is a Senior Manager heading the Protein Formulation Laboratory at Merck Life Science KGaA, Process Solutions department in Darmstadt, Germany. His team is working on delivering solutions to challenges in protein formulations stemming mainly from viscosity and aggregation of...

Baptiste Balbuena is a Biomanufacturing Engineer MSAT EMEA passioned by bioprocessing. Holder of a master’s degree in project management and biotechnologies innovation from Montpellier University, he dedicated last years to technically support customers with various problematics concerning...

Prof. Michal Bassani-Sternberg earned her PhD in Biology from the Technion – Israel Institute of Technology. From 2012 to 2015, she conducted postdoctoral research in the Proteomics and Signal Transduction Department, led by Prof. Matthias Mann at the Max Planck Institute of Biochemistry. Since...

I started my career in the pharmaceutical industry in 2000 as a Clinical Research Associate (CRA) at Pfizer, where I gained hands-on experience in clinical research from the very beginning. This role provided me with a fundamental understanding of clinical trial operations, monitoring and...

Dr Alain Beck is Senior Director, Biologics CMC and Developability (Institut de Recherche Pierre Fabre, France), co-founder and Associate Editor of mAbs journal (2009) and chairman of MabDesign SAB (2014). He is or was involved in +12 clinical stage biologics R&D programs including dalotuzumab/ ...

Julia has been researching on immune proteins already during her PhD at a leading hospital in the US. Afterwards Julia was involved in development of various therapeutics from preclinics up to clinical and market access strategy development in the industry. After combining this expertise with...

Dr. Nicola Beltraminelli joined Innate Pharma as Vice President and Chief Development Officer in January 2022 and was recently appointed as Head of Reasearch Early Development of the organization. Dr. Beltraminelli brings 25 years of biotech experience to the role, and specifically in the...

Edwige is working as a Senior Scientist in mass spectrometry at Biomedical Research, NOVARTIS Switzerland. She holds a master’s degree in analytical chemistry from the University of Rennes, France, and has acquired an extensive expertise in the characterization of therapeutic proteins over the last ...

Eli makes sure Cradle's models and algorithms are doing what we think they are doing, and he keeps an eye out for the latest and greatest techniques in the literature. He was previously at Google (Brain, Accelerated Science, Cloud) working on biological sequence design, AutoML, and natural...

Sara Bonetti is Senior Scientist at Salipro Biotech, a company located in Stockholm, Sweden, working on stabilizing challenging drug targets for drug discovery. Prior to joining Salipro Biotech, Sara obtained her PhD in Biochemistry and Molecular Biology from the University of...

Gitta Boons studied Biochemistry and Biotechnology at the University of Antwerp, where she developed an early interest in cancer research. She conducted her Master’s thesis at the Laboratory for Translational Research and Microfluidics at Paris Descartes University and pursued an FWO-funded PhD in...

Leo has served at both the UK’s and Swiss health authorities: MHRA and Swissmedic. During his tenure, he has contributed to expert groups for WHO, EDQM (Council of Europe) and EMA. His work spans assessment of marketing authorisations, regulatory advice, compliance, health policy, and public...

Prof. Frederic Bouder has developed policy-oriented research on risk communication and risk regulation, with a strong transatlantic and comparative dimension. His interest for medicines has taken central stage in his career including in the area of vaccines and biotechnology. His research interests ...

Helena Braet graduated in 2018 with a master’s degree in Pharmaceutical Sciences – Drug development at Ghent University, Belgium. The same year, she started a PhD at Ghent University at the Ghent Research Group on Nanomedicines, supervised by Prof. Katrien Remaut and Prof. Stefaan De Smedt. During...

Diego has more than two decades of venture capital experience and has developed a solid experience in creating, growing and exiting ventures in therapeutics and medical devices. He served as chairman and non-executive director in Endoart (acquired by Allergan), Endosense (acquired by St...

Dr. Luigi Buonaguro is the Director of the Innovative Immunological Models at the National Cancer Institute - IRCCS “Pascale ”, Naples – Italy. He is an expert in identification and characterization of tumor antigens for preventive/therapeutic cancer vaccine development. His focus is mostly on...

Maurizio is a biotech executive with over 15 years of experience in oncology drug development and diagnostics, specializing in translational medicine. With deep expertise in cancer immunotherapy, he has contributed to the development of monoclonal and bispecific antibodies, small molecules, and...

A/Prof Andre Choo obtained his PhD from the University of Technology Sydney focusing on the molecular engineering of antibody fragments and immunotoxins. He was also involved in the characterization of a mAb that induced apoptosis of kappa-myelomas.  This is currently pursued by HaemaLogiX in Phase ...

Anandi Chowdhury is a researcher at the Centre of Excellence for Biopharmaceutical Technology, Indian Institute of Technology Delhi, India. With over seven years of experience in biopharmaceutical research, she specializes in protein aggregation, biologic stability, and the development of...

Michaela Cohrs is a PhD candidate at Ghent University under the supervision of Prof. Hristo Svilenov and Prof. Stefaan De Smedt. Her research focuses on the analysis and prevention of antibody aggregation, with projects ranging from early candidate screening to formulation development and...

Dr. Silvia Crescioli is a Business Intelligence Creator at The Antibody Society working on business intelligence and educational research projects. Since 2021, she collaborates to the "Antibodies to watch" editorials in mAbs, reviewing antibody therapeutics recently approved or in...

Dr. Camille Dagallier is a Laboratory & Process Development Senior Scientist at Sanofi, where she has been advancing drug product development since 2015. A graduate of ESPCI Paris with a master's in polymer science, she earned her PhD in colloid physics from the University of...

Dr. Laura Daley is a Senior Director at Catalent Pharma Solution where she supports Cell Line Development, R&D, and Cell & Molecular Biology activities. Laura received her Ph.D. in Pharmacology and Physiology from the Saint Louis University School of Medicine before joining the Department...

Luminita Damian is the Business Development Manager for the Biacore and Protein Imaging portfolio at Cytiva. She has held various positions at Cytiva, building nearly 20 years of experience in the life sciences sector. She received her Ph.D. in Biochemistry from Paul Sabatier University in...

Shahrad Daraeikia is a scientist and strategist with nearly a decade of experience in antibody discovery and protein engineering. He has focused his career on developing next-generation antibody display libraries, as well as platforms for affinity maturation and humanization. Today, he applies his...

Roberto De Luca graduated in Biology at ETH Zürich. He performed his PhD studies at ETH Zürich focusing on the generation of antibody-cytokine fusion proteins for the treatment of tumors. Dr. De Luca is author of several peer-reviewed publications in international scientific journals.

Julie Deckers is a Senior Scientist in Preclinical Product Development at argenx, a leading biotechnology company specializing in the discovery and development of innovative antibody-based therapies. Argenx created an antibody innovation ecosystem where pioneering scientists and antibody engineers...

Dr Fabienne Deckert is the founder and Managing Director of Complyomics, a company supporting Life Sciences organizations with customized Quality Systems and tailored Bioanalytical solutions with a focus on compliance with regulatory requirements. With 30 years in the international Pharma industry ...

Gundo Diedrich is Executive Director of Antibody Engineering at MacroGenics. His work focuses on the discovery, engineering, and expression of antibodies as well as the development of the company’s multispecific antibody platform. Gundo received a Ph.D. in Chemistry from the Max-Planck Institute...

Michaela leads Patient Engagement at Novartis. In this role she is responsible for the PE strategy and systematic implementation across the company portfolio, starting at early development stage, through to regulatory and value dossier submissions. This work is based on long term strategic...

Patrick Doonan, Ph.D. is a Director of Alliance Management and Antibody Engineering at Ailux. He brings over a decade of industry experience in the field of antibody drug discovery from target ID to FIH. During his tenure at Pfizer and Janssen, he published several high impact journals, furthering...

Current experience: Dr. Joan D'souza is a Pharmacovigilance Physician and a Consultant. She has expertise in pre and post-marketing safety surveillance of drugs and medical devices. Previous experience: A firm believer in sharing her knowledge: The DIA, World Drug Safety Congress; ...

Stefan Dübel is Full Professor of Biotechnology and Director of the corresponding department at the Technical University of Braunschweig, Germany. After completing his PhD at the University of Heidelberg, he joined the German Cancer Research Center (DKFZ) in 1989, where he pioneered in vitro...

Dr Anselm Ebert, PhD holds the position of Business Development Director at H&T Presspart. Dr Ebert oversees the strategic management of the new product development process and manages new product introductions for H&T Presspart. Before joining H&T Presspart he was Director of Product...

Patrick is the Clinical Environmental Sustainability Lead at Novartis, responsible for integrating Environmental Sustainability mindset, principles and practices across all trial stages & relevant business processes. In his role he works with study teams across Novartis Development as well as...

Marisa has >10 years of experience in life sciences and therapeutics, specializing in gene therapy, neurotechnology, and business development. She joined Oligo Factory in May 2024 as the Director of Business Development covering the Western US & Asia-Pacific regions where she leads strategic ...

Christian is a Managing Director on the Healthcare team and brings a combination of medical, transaction and entrepreneurial experience to Inflexion.He started his career as a doctor in major London teaching hospitals after qualifying at Imperial College, where he was awarded multiple academic...

I have more than 20 years of experience in the pharmaceutical industry and have held various positions in clinical trial management, procurement and medical affairs. As an Industry Clinical Collaboration Leader, I focus on bringing new and innovative treatment combinations to patients through...

Alejandro is a Global Principal Scientist at Lonza with a focus on Upstream Process Development. Alejandro has over 15 years of experience in Biopharma working in R&D and commercial areas, where he has supported the development of a wide range of products (e.g., complex recombinant...

Kevin began his career at Cambridge Antibody Technology (now part of AstraZeneca) when CAT was still in its start-up phase. He went on to found and manage Isogenica Ltd and has since held CEO positions with PhosImmune Inc., Activiomics Ltd and F-star GmbH. Kevin studied for his PhD in the...

Nuno Fontes is the SVP, Head of Global CMC at WuXi Biologics, reporting directly to Dr. Chris Chen, CEO.  Nuno brings 24 years of global biotech industry experience spanning large pharmaceutical companies and small biotech firms in technical operations and CMC management. Prior to joining WuXi...

I am a researcher in Translational Modelling & Simulation at Roche. I support large molecule projects through model-based predictions that e.g. support the optimization of compound dosing schedules, predict First-In-Human dosing or select a lead drug candidate. I also develop in silico models...

Tim Fugmann, CSO and Co-Founder of Alithea Biotechnology, holds a PhD from ETH Zurich and was 10 years in biotech industry in Switzerland before being appointed Prof. for mass spectrometry-based proteomics in Giessen, Germany. For many years, he is studying HLA-presented peptides in health and...

Dr Frank Gesellchen is an Assay Development Manager at Sphere Bio, where he leads the design and optimization of innovative assays for single-cell microfluidic platforms, enabling breakthroughs in antibody discovery, cell line development, and cell therapy research.Frank earned his Ph.D. in Biology ...

Ettore Gilardoni is Head of Mass Spectrometry at Philochem AG. The team main activities vary from biodistribution of small organic molecules in biospecimens; biopharmaceuticals characterization, and proteomics application for target identification; host cell proteins characterization, and mechanism ...

PhD, Professor, Head of RG Biotherapeutic Glycoengineering & Immunology, DTU Bioengineering, Technical University of Denmark. Focus on novel bi- and multispecific antibody and cell-based therapeutics in immunooncology and infectious diseases. After early career in academic research, e.g. MDC in ...

Professor Torbjörn Gräslund holds a Ph.D. in Biotechnology from KTH - Royal Institute of Technology, Sweden, since 2001. Following two years of post-doctoral training with Professor Carlos Barbas at the Scripps Research Institute, he has been a principal investigator at the Department of Protein...

Christina Greitens is a PhD Student at ETH Zurich and holds an M.Sc. in Bioengineering from KIT in Germany. Before joining the Drug Formulation and Delivery Laboratory of Prof. Jean-Christophe Leroux, she worked as a Scientist at Lonza in Formulation Development. Prior to that, she held diverse...

As ATUM’s Co-Founder, Dr. Claes Gustafsson oversees most of the company’s external communications and is actively engaged in developing ATUM's technology platforms. Prior to co-founding ATUM in 2003, Claes managed key strategic teams at Maxygen Inc and worked as a scientist at Kosan...

Ana Isabel Gutiérrez joined H&T Presspart in 2023 as Global Business Development Manager driving the company’s innovative Parenteral Applications Program.Before joining H&T Presspart, Ana spent over 12 years at West Pharmaceutical Services, where she held a prominent sales leadership...

10+ years industry experience in developing biologics and radiopharmaceuticals mainly in the field of oncology, in technical and commercial roles.

Julia Harwardt is a Bench Scientist in the Antibody Discovery & Protein Engineering department at Merck KGaA. She joined the company after completing her PhD in the group of Prof. Dr. Harald Kolmar at the Technical University of Darmstadt. With a strong background in biochemistry and antibody...

Luluah Hashim Husain is a seasoned finance professional with a strong background in the biopharmaceutical industry. Currently serving as the Global Head of Finance for Biosimilars at Biogen, Luluah brings a wealth of experience and expertise to her role. With a proven track record of driving...

Winston is the VP Computational Sciences and Engineering at LabGenius, where he leads a team of experts in data science, machine learning, and software development to expand LabGenius’ ML-driven discovery platform capabilities. He has extensive experience leading the development and application of ...

Hooman is currently an Associate Professor at the Technical University of Denmark where his research group broadly aims to engineer mammalian cells for improved cellular behavior in fields including biologics manufacturing and cultivated meat. He previously led the Omics and Modeling Team in...

Charles Heise is Associate Director in the Bioprocessing Strategy & Development group at FUJIFILM Biotechnologies working on developing connected, integrated processes.  He has over 15 years of experience in the biologics industry leading the development of cGMP processes for clinical and...

Dr. Alexander Hempelmann is a German structural biochemist specializing in antibody engineering and protein interactions. He currently serves as a Group Leader for ADC Technologies at Heidelberg Pharma in Ladenburg, Germany, where he focuses on advancing antibody-drug conjugate (ADC) platforms. His ...

As Head of Corporate Scientific Engagement at Genedata, Jana leads the advancement of data, analytics, data science, and AI within the biopharma R&D landscape. Since joining Genedata in 2018, Jana has held several positions shaping product development, marketing strategies, and scientific...

Oliver Hill – Senior Director Protein Engineering, YUMAB GmbH Oliver Hill is an experienced biotechnology professional specializing in protein engineering and drug discovery. Currently, he serves as Senior Director of Protein Engineering at YUMAB GmbH, focusing on advancing antibody-based...

Axel joined Bioassay in 2007 as Scientists after covering the role of Laboratory Head of Department of Cell and Molecular Biology at Biotest AG. Upon joining Bioassay Axel quickly rose through the ranks and became Managing Director in 2010. In his new role he was involved in the acquisition of...

Sebastian Hörner joined BiconY Therapeutics as a Senior Scientist in 2023. He studied technical biology at the University of Stuttgart from 2011 to 2017, where he started his work in the field of recombinant antibodies in the lab of Roland Kontermann. From 2017 to 2021, he worked as a PhD candidate ...

James has over 12 years’ experience focusing on the formulation sector. Working at Croda he has focused on formulating with Croda’s current range of surfactants, oils and other speciality chemicals used in formulated products from paints to pharmaceuticals to engine lubricants. James lead the new...

Originally from Canada, Dr. Melita Irving began working in the field of T-cell engineering for cancer immunotherapy in Switzerland in 2007. She has been a group leader at the Ludwig Institute for Cancer Research in the Department of Oncology at the University of Lausanne for the past 12...

Dr Jagielska specializes in molecular biology, protein engineering, and medical biotechnology. Her research focuses on the development and application of bacteriolytic proteins – enzymes with antimicrobial properties represent a promising alternative to traditional antibiotics in the treatment of...

Dr. Shashi Jatiani is Director of Strategic Partnerships at SeromYx, driving growth through key technical and commercial collaborations. He bridges science and business by shaping partnership strategies and translating complex concepts into actionable plans. Shashi represents SeromYx at scientific...

Master in Political Science from the University of Copenhagen 45+ years of professional experience, including: Head of section in the Ministries of Social Affairs and of LabourLabour Counsellor at the Danish UN-mission in GenevaHealth Counsellor at the Danish EU-representation in BrusselsSpokesman...

Veronika is Medical Director at MSD, where she oversees vaccine programs from protocol design through global regulatory submissions and approval readiness. Since joining MSD in 2018 she has led multiple vaccine trials across diverse populations and regions, coordinating cross‑functional teams and...

Valentin Junet has 6+ years of experience in developing data-driven solutions to solve complex biotech problems. After a master’s degree in applied mathematics at ETH Zurich, he received his Ph.D. in Bioinformatics at the Autonomous University of Barcelona as part of a collaborative project funded...

Translational B cell and cancer immunologist with academic and biotechnology experience in the UK and USA. She heads a cancer antibody discovery team focusing on dissecting the crosstalk between human immunity and solid tumours and understanding the impact of antibody isotype on therapeutic...

Dr. Aneesh Karatt-Vellatt is Chief Scientific officer and co-founder at Maxion Therapeutics Ltd (Cambridge UK), a company focused on developing antibody treatments for diseases driven by ion channels and GPCRs. Dr Karatt Vellatt was also co-founder of IONTAS Ltd and holds a PhD in Biochemistry from ...

Dr. Anette Karle is a seasoned expert in the immunogenicity field. She acquired her PhD in 2008 on the topic of altered antigen presentation in nitrated pollen allergens, applying the MAPPs technology. Joining Novartis in 2009, she pioneered the establishment of technologies for assessing the...

Inventor of the P5 Platform to generate stable ADCs during Phd with Prof. Christian HackenbergerJoint Tubulis as Co-Founder in 2019Leads Tubulis Chemistry and Early Discovery efforts as VP

Dr. Divor Kiseljak earned his Master’s in Molecular Biology from the University of Zagreb in 2008 and went on to complete his PhD at EPFL in Lausanne, where he specialized in protein expression and cell line development. His research on transient gene expression in HEK cells, including achieving a...

​​​​​​​Arjen Kramer studied Chemistry and obtained a Ph.D. in Enzymology & Protein Engineering at Utrecht University in The Netherlands. Arjen then worked for 5 years at biotechnology company Crucell (now Johnson & Johnson) in Leiden, The Netherlands, specializing in phage display selection ...

Carsten Krantz, PhD, is a highly accomplished bioanalytical scientist with broad expertise across a spectrum of advanced methodologies, including LC-MS/MS, ligand binding assays, ELISA, MSD, and neutralizing antibody assays. Currently serving as an Associate Director at Novartis, he leads a global...

Emanuel Kreidl is a seasoned Senior Expert and Principal Scientist at Novartis, with a strong background in biologics research and development. With over 15 years of experience in the pharmaceutical industry, Emanuel has made significant contributions to the field of biologics, particularly in the...

Professor Jaya Krishnan has had a successful career spanning over two decades in cardiovascular research and biotechnology entrepreneurship. He obtained his PhD in biochemistry with a specialization in molecular oncology at the Forschungszentrum Karlsruhe (now the Karlsruhe Institute of Technology) ...

Peter Kristensen is Professor at the Department of Chemistry and Bioscience, Aalborg University, Denmark. He holds a Ph.D. and M.Sc. in Biostructural Chemistry from the University of Aarhus. With a career spanning over two decades, his academic journey is marked by significant contributions to...

Dan Bach Kristensen holds a Ph.D. in biology and B.Sc. degree in chemistry. Dan is specialized in protein chemistry and mass spectrometry, which he initially applied in the field of proteome research. For the last 19 years Dan has been working with analytical development in the biopharmaceutical...

2024Yumab GmbH VP Services & Operations2016-2024Yumab GmbH Project manager2014-2016Technical University of BraunschweigPhD student, Department of Biotechnology.2008-2014University of Heidelberg Study of Molecular Biotechnology (Bsc/Msc).

Anil Kumar holds a Ph.D. in Protein Engineering from NTU, Singapore, and brings over a decade of experience in biopharmaceutical R&D, with expertise in protein design and therapeutic innovation for immune-oncology and autoimmune indications. Prior to joining KACTUS Bio, Anil served as Director...

Mayra Latorre-Martinez currently works at Swissmedic, in the Department of Clinical Trials where she is responsible for the evaluation and authorization of Clinical Trials. She is also Swissmedic representative at the Access Consortium Clinical Trials Working Group. Mayra worked at the Regulatory...

Dr. Beau le Roy is a Technical Sales Supervisor at ACROBiosystems, where he contributes to the integration of advanced pharmaceutical solutions with a focus on life sciences. With a PhD in Pharmaceutical Sciences and over a decade of experience in pharmaceutical research, he brings deep technical...

Passionate for helping patients prevent blindness and vision loss, Leading the Ophthalmology Clinical Development group at Bayer, striving to find innovative solutions to take from research to clinical practice, Growing Bayer's impact in caring for patients with visual impairment. ...

Bernd is a border-crosser between the worlds of regulatory and clinical development of biopharmaceutical compounds. A seasoned executive with demonstrated experience of 25+ years’ working in academia (West German Cancer Center, University of Essen Medical School), in regulatory agencies (PEI, EMA)...

Britta Lipinski is a PhD candidate in the Antibody Discovery and Protein Engineering Department of Merck KGaA, supervised by Stefan Zielonka, where she works in close collaboration with the group of Prof. Dr. Harald Kolmar at the Technical University of Darmstadt. Her research focuses on the...

Dr. Margaux Longuespée obtained her PhD of chemistry at the University of Strasbourg (France) in 2016. She then dedicated her activities to the development of mass spectrometric (MS) methods for clinical pharmacology and personlized medicine at the University Hospital of Heidelberg (Germany). With...

Dr. Rémi Longuespée obtained a PhD in Life Sciences at the University of Lille (France) and a PhD of Biochemistry at the University of Sherbrooke (Canada) in 2012. He dedicated a major part of his career to the development of methods in mass spectrometry for applications in clinics, from anatomical ...

Christian Lotz studied Physical Chemistry at the University of Bochum Germany and did his doctorate in Physical Chemistry at the University of Essen in Germany. He started his Industry career at Lipoid GmbH, a GMP manufacturer of parenteral grade phospholipids, in the sales department with...

Robin Löving, Chief Scientific Officer (CSO) at Salipro Biotech. Robin has more than 15 years’ experience working with therapeutically interesting membrane proteins. He did his PhD with a focus on membrane proteins and antigen design at the Karolinska Institute in Stockholm, Sweden. After being...

I, Nirmal Mallick, is currently pursuing research at Indian Institute of Technology, Delhi in the area of Bioreactor Design and process optimization under the guidance of Prof. Anurag S. Rathore. During this research I worked with the geometry of different size of reactor starting from 0.6 ltr to...

Melanie has been a valued member of Sartorius for nearly a decade, bringing extensive expertise in CHO cell line development for biosimilars and novel biologic entities (NBEs), as well as molecular and cell biology, bioprocess optimization, and transfer to contract development and manufacturing...

Julie Maréchal-Jamil is a seasoned professional with over 15 years of experience in the pharmaceutical industry. Currently serving as the Senior Director of Pharmaceutical Policy at Medicines for Europe, she is a respected expert in the field of biologics and healthcare policy. Julie's...

Dr Daniela Marino is the Co-Founder and CEO of CUTISS AG. Daniela holds a Master in Biotechnology from the University of Milano and a PhD in Sciences from ETH Zurich. With her focus on vascular and stem cell biology, in 2009 she joined the Tissue Biology Research Unit of the University of Zurich as ...

Aimee Mattei, MS. is the Director of Bioinformatics at EpiVax. She manages a team of analysts and project managers providing in silico immunogenicity risk assessments supporting research, collaborative, and commercial projects. She leads the development of novel in silico methods and tools for...

Irwin Matyjaszczyk holds a PhD in molecular biology from the University of Wroclaw. He spent six years at Pure Biologics, where he was responsible for antibody discovery and optimization as well as method development in projects that progressed to clinical research. In 2024, he joined...

Carrie Maynard is Associate Director of Commercial Development at Lightcast Discovery, a biotech company developing tools for single-cell functional analysis. She works with research teams across academia and industry to build strategic collaborations that bring innovative, function-first...

Drug discovery professional with hands-on experience across the full discovery value chain in different therapeutic areas — from project initiation to early clinical studies. CURRET  POSITION Senior Principal Scientist at Novatis Biomedlcail Research in the Immunology Disease Area, leading drug...

Fabien Menissez is Business Development Manager at Alga Biologics, where he drives strategic partnerships and growth in the biologics sector. With a strong background in biotechnology and expertise in market development, he focuses on innovation and collaboration to create value for clients and...

Virginia Metrangolo is a Medical biotechnologist working as a postdoctoral researcher in the Engelholm research group at the Finsen Laboratory/Biotech Research and Innovation Centre in Copenhagen. Her research work involves the development of antibody-based therapies, mostly antibody-drug...

Dr. Anika Mijakovac is an expert associate at the Faculty of Science, University of Zagreb and a senior researcher in Genos working in the field of epigenetics and protein glycobiology. Her primary focus is immunoglobulin G (IgG) glycosylation in aging and disease. In her research she uses...

Dr. Michel Mikhail has more than 30 years Pharmaceutical Industry experience and track record of achievement in R & D and International Regulatory Affairs in large multinational Research-based pharmaceutical Companies as well as Generic & Biosimilars companies. He also has global experience ...

Jeffrey is Vice President of Regulatory at Abzena, based out of the company’s Bristol, PA facility. With over 30 years of experience in drug development,  Jeffrey leads product strategy, regulatory planning and quality management initiatives across early development and manufacturing. Before...

Anca Moldovan is a pharmaceutical quality and operations strategist with over 10 years of experience in EU-regulated markets. She currently serves as Director of Operations & Quality at Tetris Pharma and is the founder of Sefala QP, a consultancy focused on modernizing quality systems for...

Since 2024, Lorenzo has worked as an independent advisor, collaborating with national governments and international organizations to promote partnerships for medicine development and strengthen regulatory systems. Previously, he led the work on access to innovative treatments and technologies at...

Mauricio Morales-Castillo is the Associate Director of Global Medical Biosimilars at Abbott’s medicines business. Prior to joining Abbott, Mauricio worked at Novartis LATAM, where he led the medical team for Cardiovascular and Respiratory, and established the Real-World-Evidence (RWE) and...

After completing his Ph.D. studies in 2009 in microfluidic chip field, he continued as postdoctoral fellow at Institut Curie in the team of Jean Louis Viovy and developed thermoplastic chips for diagnostics. In 2013, he went on to apply droplet microfluidics for the study of molecular evolution in...

Julien's career has been devoted to the discovery & development of new technologies to help solve of the world's most complex design challenges, from the treatment of human diseases by creating new therapeutic libraries, to the manufacture of smart nano-electronics & 3D...

Dr. Lukas Naumann is a dedicated Scientist specializing in Analytical Chemistry with a focus on Process Analytical Technology (PAT) at Roche. With a strong background in biochemistry and pharmaceutical sciences, Lukas brings a wealth of expertise to the field of biologics. His research interests...

Leman Nur Nehri is a computational biologist with a PhD in Biologial Sciences, specializing in the integration of multi-omics data with probabilistic modeling to uncover regulatory mechanisms and therapeutic targets in cancer. Her expertise spans multi-omics data analysis and modeling, with a...

Björn Niebel is a Senior Principal Scientist, Group Head in the Discovery Department of the Nanobody Research Platform at Sanofi Ghent. Björn received his master’s degree in Chemistry from the University of Braunschweig, Germany in 2006 and holds a PhD in Biochemistry from the University of...

Sandip is a downstream scientist at the Gene Therapy Process Sciences division of UCB Pharma in Belgium. He has worked for different organizations for 13 years, developing downstream processes for various biopharmaceuticals, such as fusion proteins, viral vectors, monoclonal antibodies, and...

Kalyani is a biopharmaceutical professional with 30 years of experience in various aspects of biologics, such as CMC development, CMC regulatory, large-scale manufacturing, launch and commercialization.  She worked across multiple therapeutic areas...

Rob is currently Senior Scientist at Etcembly, where he leads the protein engineering pipeline in biologics development. After completing his PhD in structural biology at the University of St Andrews, Rob spent six years studying TCR-ligand interactions using various biochemical assays coupled with ...

Isabelle Petit Topin is a passionate professional for Protein biochemistry and all that has to do with protein in general. Graduated at the University Paris Diderot, Isabelle obtained her PhD in 2009 (CIFRE HRA Pharma - Inserm - Paris) in Protein Biochemistry and Crystallography. After her...

Dr. Birgit Piater is an accomplished scientist with over ten years of experience in the pharmaceutical industry, currently serving as the Head of Laboratory for Antibody Drug Conjugates (ADC) Biology at Merck KGaA, Darmstadt, Germany. In her role, she leads a dynamic lab team focused on advancing...

I am a research scientist and the head of protein expression and purification at SelekTx where we are investigating GPCR selektides. Selektides are constrained peptide scaffold biomolecules that are highly selective to individual GPCRs. I am investigating GLP-1R and CB2R specific selektides in...

(ChatGPT): Andreas Plueckthun is a distinguished Professor of Biochemistry and the Director of the Department of Biochemistry at the University of Zurich. With a strong background in protein engineering and molecular biology, he is a renowned expert in the field of biologics. Dr. Plueckthun's...

Dr Plyte has over 25 years of experience in drug development both in Big Pharma and Small Biotech predominantly applied to Oncology and immuno-Oncology. Over the last 15 years he has focussed on the development of biologics with an emphasis of multi-specific antibody formats having differing drug...

Ioana has been heading up the Global Market Access Strategy for Abbott’s medicines business for the past two years. Prior to this role, she held various positions in Novartis, Sandoz, GlaxoSmithKline, in market access, marketing, public affairs, and R&D based in the...

Philipp Probst is Director of ADC Research at Araris Biotech AG, a Swiss biotech company located in Au ZH pioneering a novel linker technology for antibody-drug conjugates. He studied Pharmaceutical Sciences and received his PhD from ETH Zürich in 2018, where he worked in the group of Prof. Dario...

Chief Operating Officer of the Philogen Group and Board Member of Philochem AG (Philogen discovery center). Graduated in Medicinal Chemistry at La Sapienza University and performed Ph.D. studies at ETH Zürich focusing on the generation of antibody-cytokine fusion proteins for the treatment of...

Dr Andy Racher is the Director of Commercial Operations at SynGenSys Ltd. With over four decades in the biotech sector, including a distinguished 20-year tenure at Lonza Biologics, Andy has a wealth of experience covering cell engineering, expression systems, cell line and process development, plus ...

Dr. Rafei is an immunologist by training focused on the development of therapies within the immuno-oncology space. Throughout the past decade, he accumulated profound knowledge and insight in the fields of T-cell development, stem cell biology, cancer immunotherapy and autoimmune diseases. While...

Tobias is a mass spectrometrist at Roche Pharma Development in Germany. Coming from the Italian alps, he studied chemistry in Austria and Scotland. Among other responsibilities, his work focuses on advancing the in-depth characterization of novel biopharmaceuticals. Being a passionate...

Alexander joined Anaveon in 2022 as a protein engineer, focused on developing the next generation of antibody-cytokine fusion proteins for cancer therapy. He previously worked at a biotech company, focusing on the generation of antibody therapeutics for immuno-oncology. He also has a strong...

Katharina Reefschläger is a Technical Sales Specialist at Bio-Rad, focusing on the innovative Pioneer Antibody Discovery Platform. With over a decade of experience in scientific sales and customer support, she brings deep biological expertise and guidance in antibody development and research...

(9) Ramona Reichenbach | LinkedIn

Valéry Risson is a seasoned professional in the biopharmaceutical industry, currently serving as the Director of RLT Value & Access International at Novartis. With a strong background in market access and pricing strategies, Valéry brings a wealth of experience to the table. Throughout her...

Professor in directed evolution and antibody technology at KTH Royal Inst.Technology, Sweden. Director of GeneNova, a center focused on developing platforms for more cost effective, safe and efficacious AAV-based gene therapy through interdisciplinary industry and academia collaborations. He is an...

Luis is a Specifica-IQVIA Scientist who leads antibody discovery, affinity maturation and characterization campaigns using Specifica’s antibody discovery platform. Luis holds a PhD in Biochemistry from the University of Sao Paulo, Brazil. During his PhD, he gained experience in small-peptide phage...

Ali Roghanian is an Associate Professor in Cancer Immunotherapy at the University of Southampton, UK. With a background in basic and translational immunology and a focus on cancer research, Ali is dedicated to advancing the field of biologics and immunotherapy. His research interests lie in...

Thomas Rose, PhD, is Head of Expression Systems at ProBioGen. He received his MSc in Biotechnology from the University of Applied Science in Berlin, his PhD in Biochemistry from the Free University of Berlin and joined ProBioGen in 2001. His work focuses on cell line development and expression...

Christine Rothe serves as Chief Development Officer at iOmx Therapeutics where she is responsible for research and development programs. Christine has a long-standing track record in discovery and development of drug candidates. Before joining iOmx, Christine held positions of increasing...

Izabela Sabala brings a strong background in protein biochemistry, along with deep insight and practical strategies to her work. Her research is focused on engineering of a new class of antimicrobials—enzybiotics. These are enzymes with exceptional antimicrobial activity, currently being developed...

Nicolas Sabarth is heading a biotherapeutics discovery group at Boehringer-Ingelheim Vienna, Austria. He received his PhD from the Max-Planck-Institute for Infection Biology, Germany.  Since then, he held positions of increasing responsibility in the R&D departments of...

Giorgio is part of the Business Unit, with responsibility of coordinating Business Development and Post sales activitiesHe joined BSP Pharmaceuticals in 2008 as Manufacturing Manager; in this role he was an active member of the team in charge of building up the manufacturing plant, including...

Aaron is the Chief Strategy Officer at Adimab, with over 25 years of experience in biotechnology, focusing on discovering and developing novel first-in-class antibody therapeutics. Before joining Adimab, Aaron served as the Chief Scientific Officer of Twist Bioscience, where he led their Biopharma...

Ulrike Scheffler is the Senior Director of Business Development at Icosagen CRDMO, specializing in advancing complex recombinant proteins from discovery to GMP readiness. With 16+ years of experience, Ulrike combines a strong technical background from her time as a scientist at Roche Glycart with...

PRISM was founded in 2009 by Dr. Schnitzer, a world-renowned expert in vascular biology with almost four decades of research experience.  Upon earning his MD in 1985 from the University of Pittsburgh, he served as a Post-Doctoral Fellow in the Department of Cell Biology, Yale University Medical...

Christian is the co-founder and CSO of the biotech company Numaferm that was founded 2017 as a spin-off of the University of Düsseldorf, Germany. He is biochemist and biotechnologist by education and completed his PhD in the field of type 1 secretion systems at the same university between 2009 and...

Oliver Seifert is a senior scientist in the laboratory of Roland Kontermann at the University of Stuttgart and leads the bispecific antibody group. He is an expert in the field of antibody engineering with more than 20 years experience. His scientific research covers development and...

Dr. Sly has over 25 years of experience in biomanuacturing, spanning across R&D to clinical production. Dr. Sly has established a wide network of collaborators in the bioprocessing Industry, including patent-holding biopharmaceutical companies, contract research organizations (CROs), and...

Cláudia is a trained Pharmacist and obtained her MSc from the University of Coimbra, in Portugal. She started her career at a CDMO with a focus on cell line and cell culture development. Cláudia joined the USP team at CDR-Life over two years ago and is now Lead Scientist in the Drug Substance...

Frank Staal was trained in biomedicine at the Faculty of Medicine of Utrecht University, the Netherlands. He obtained both his Bachelor and Master degrees cum laude from this university and then moved to Stanford University, CA USA, for his PhD degree in Genetics under supervision of the late...

After earning his degree in Medicine in 2009 from the Campus Bio-Medico University of Rome, he completed an international PhD in type 1 (autoimmune) diabetes at the same university and at Queen Mary, University of London (supervisor Prof. Ahuva Nissim). He subsequently obtained his specialty in...

Dr. Svilenov is an Associate Professor of Biopharmaceutical Technology at the Technical University of Munich (TUM). His research focuses on the development, formulation, and manufacturing of biotherapeutics. In 2024, he was awarded an ERC grant to advance novel antibody-based therapeutics.Prior to...

Hamed T. Ghomi is a scientist with over a decade of experience in computational molecular design, with a focus on peptide and protein engineering. He has led projects across industry and academia, including roles at companies such as Illumina, where he contributed to innovations in enzyme design...

Jian Tang is an Associate professor at HEC's Department of Decision Sciences. He is also an Adjunct professor at the Department of Computer Science and Operations Research at University of Montreal and a Core Academic member at Mila - Quebec AI Institute. He is a Canada CIFAR AI Chair and the...

Anike Te is an industrial strategist, honorary professor and advisor focused on strategic growth and innovation. Anike was appointed as Chief Strategy Officer of Lucideon in 2018, where she previously served on Lucideon’s Group Business Development Board and is currently a member of the Strategy...

Bert is currently Senior Vice President, Business Development of Bio-Thera Solutions, a China-based pharmaceutical company, joining the company in 2017. Prior to joining Bio-Thera Solutions, Bert was the CEO of the Sarcoma Foundation of America (SFA), a rare cancer patient advocacy...

Gudrun Thorhallsdottir is a Research Associate Scientist at Philochem AG and Doctoral student at ETH Zürich, where she focuses on the development of novel antibody-based therapeutics. 

Dr. Jakub Tomala earned his Master Science degree and Ph.D., both in Immunology, at Charles University in Prague, Czech Republic. After completing a postdoctoral fellowship at Johns Hopkins University, School of Medicine, in 2018, Dr. Tomala became senior researcher in the Laboratory of...

Dr. Marco Traub has gained considerable experience in several research, management, and educational projects over the past 25 years. He is the founder of the Trans European Stem Cell Therapy Consortium (TESCT) and acts since 2005 as Chair of the TESCT consortium and as EU-Commission Expert...

Lorenzo Turelli is a Postdoctoral researcher within the CBST unit of the University of Strasbourg, carrying out the scientific activity on the development of a novel format of Antibody-Drug Conjugates (ADCs). His research in chemical biology focus on the development of novel linker modalities for...

Mikko Turunen, PhD, Founder of RNatives and Adjunct Professor of Molecular Medicine at the University of Eastern Finland, has +28 years of experience in the development of gene therapies. Throughout his career, his research focus has been non-coding RNAs in transcriptional gene regulation. He was...

Laura Unmuth is a Bench Scientist and PhD candidate in the Antibody Discovery & Protein Engineering department of Merck KGaA, supervised by Stefan Zielonka and in collaboration with the group of Prof. Dr. Harald Kolmar at the Technical University of Darmstadt. Her research work focuses on the...

Stefanie Urlinger is Chief Scientific Officer at Cimeio Therapeutics, a biotech company developing state-of-the-art immunotherapies, along with paired, engineered hematopoietic stem cells. Stefanie has over 20 years of expertise in large molecule engineering and early development and has led...

Thomas Valerius studied medicine at the University of Erlangen-Nürnberg, Germany. After his training in internal medicine, he specialized in Hematology/Oncology and Rheumatology. Since May 2003, he has been working at the University in Kiel, Germany, where he currently is assistant professor at the ...

Joshi Venugopal is the General Manager and Head of Europe for Novartis Gene Therapies &Rare Diseases. He is also a Board Member of Somagenetix, a Zurich based biotech company developing gene therapies. A seasoned pharmaceutical executive, Joshi brings a unique blend of experience across...

Dr. Wouter Verdurmen is an Assistant Professor at Radboud University Medical Center, specializing in biologics and immunotherapy. He studied Biomedical Sciences at Radboud University Nijmegen (the Netherlands) and obtained his PhD cum laude in 2012, focusing on the cellular delivery of...

Pieter Voermans is the Head of Clinical Data Management at Sobi, a leading biopharmaceutical company dedicated to developing innovative therapies for rare diseases. He is an experienced (25+ years) Clinical Development Leader specialised in Data Management with broad international Drug Development...

2015-2020: Scientist at Genentech,Since 2020: Head of Biology / VP, Biology and Translational Research at TubulisScientific training background: molecular cell biology, protein degradation, cellular protein homeostasis

Bjørn Voldborg has more than 20 years of experience working with recombinant protein expression from both academic and industrial settings. From 2001-2008, Bjørn was team leader in the biotech company Pharmexa A/S, responsible for molecular cloning and expression of protein-based drug...

Johannes vom Berg is a group leader at the Institute of Laboratory Animal Science (LTK), University of Zurich, Switzerland since 2019. Before that his main occupation was to direct the LTK transgenic mouse core facility of the University of Zurich from 2014-2018. He studied biology and molecular...

Romain is a senior scientist at the Ludwig Institute for Cancer Research of the University of Lausanne. He earned his PhD in immune response to transplantation and further studied mechanisms of immunosuppression involved in the tumour microenvironment (hypoxia and acidity). He is interested in...

Born in Bochum, Germany, in 1984, with a passion for science and a drive for discoveryStudied biochemistry at the Ruhr University Bochum, graduating with a Master of Science in Biochemistry in 2009Awarded a Ph.D. (summa cum laude) in Chemistry and Biochemistry from Heinrich-Heine University...

Frank Walsh is the founder and CEO of Ossianix a privately held Biotechnology company that focuses on single domain VNAR antibodies with with a major interest in brain shuttles for Neurodegenerative diseases Formerly, Frank was head of Discovery Research worldwide at Wyeth Pharmaceuticals in...

I am a Group Leader at Cancer Research Horizons and the CRUK lead for the Joint AZ-CRH Functional Genomics Centre. With over 10 years' experience, I specialise in functional genomics and preclinical oncology R&D. Before joining Cancer Research Horizons in 2019, I led target discovery and...

Dr. Wang is currently a senior principal scientist at Genentech (Roche) with more than eighteen years of working experience in antibody biologics. His responsibilities include developing and implementing discovery strategies for antibody-based biologic drugs, driving and evolving antibody molecules ...

Jörg Wischhusen studied biochemistry in Tübingen, Germany. During his thesis on mechanisms of immune escape in glioma (mentored by Michael Weller and Hans-Georg Rammensee) he performed early work in the field of experimental immune checkpoint blockade. In 2005 he was recruited as a junior research...

Frederick joined MSD in November 2016 to build a European Vaccines Clinical Development Unit in Europe. His team now has four members. This team designs, sets-up, conducts, monitors, analyzes, closes out and publishes clinical trials and PDTs within a broader clinical trial teams for vaccine...

Artur Yakimovich obtained his PhD from the University of Zurich, where he trained in two PhD programmes simultaneously: Molecular Life Science and Interdisciplinary PhD program. During that time Artur worked on developing novel machine learning (ML) and computational modelling approaches to...

Dr. Yi-Ru Yu is currently a Senior Scientist at Pilatus Biosciences SA. He obtained his B.S. in Life Science and M.S. in Genomic Science from National Yang-Ming University in 2008. Dr. Yu then pursued a Ph.D. in Prof. Chun-Ming Chen's lab, where his research focused on the congenital diseases...

My passion are science and people. Hence,  it appealed to me to study medicine and following undergraduate studies in Berlin, I went into surgery in the UK and Germany,  and eventually I found my passion in surgical oncology, caring for patients with breast cancer, sarcoma, melanoma and many other...

Joe holds a BS from Fudan University and a PhD from University of Delaware, followed by postdoctoral trainings at Lankenau Medical Research Center and Zeneca Pharmaceuticals. Prior to joining Harbour BioMed, he was in small biotechs (Pharmacopeia and Ligand Pharmaceuticals) and large MNC (BMS). ...

Dr. Marie Zhu is currently CTO of WuXi XDC with >28 years of experience in drug development at Pfizer, BMS, Xencor, Astellas, and RemeGen. She has led and involved in various novel ADC developments in the past 15 years winning 10+ ADC INDs approved by FDA and 2 ADC BLAs (Padcev approved by...